The most recent edition of the Journal of Biomolecular Screening focused on the significant advances made recently in the field of compound management. In this special edition over half of the sixteen articles specifically mention the Labcyte Echo® liquid handlers.
Of particular interest is the article by Grant et al., AstraZeneca, which states, “In summary, the introduction of the Echo acoustic reformatter has represented a major milestone in pharmaceutical screening applications. It has revolutionized the compound management process to support HTS.”
In the paper by Zaragoza-Sundqvist et al., Astra Zeneca, the authors said, “Four years ago, the first acoustic droplet ejectors (ADEs) were launched on the market, providing a new generation of high throughput noncontact liquid handlers that outclassed traditional contact instruments in almost every respect...Higher quality is achieved through greater accuracy and precision, whereas lower sample volumes can be used, and 1536 plate formats have become a reliable reality.”
Articles by Matson et al., Bristol-Myers Squibb, Pfeifer and Scheel, Novartis, and Blaxill et al., GlaxoSmithKline, use the acoustic auditing capabilities of the Labcyte Echo technology to determine the volume of wells and the level of DMSO hydration.
Labcyte Echo liquid handlers use sound to move a wide range of liquids. Eliminating physical contact with the sample makes the transfer contamination-free for a wide range of life science applications. The system has a working range from 2.5 nL to many microliters.
Echo liquid handlers automatically measure the depth of fluid in each source well, informing the user of the quantity and quality of samples. This technology is especially well suited to biological applications in which precision measurements are critical and cross-contamination of samples can interfere with accurate interpretation of the results.